1 citations
,
October 1990 in “The Lancet” Using minoxidil for hair growth may cause skin lesions in some people, and taking breaks from nitrate patches for angina might worsen symptoms.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
89 citations
,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
4 citations
,
October 2025 in “Science Advances” VCAM1 appears early in kidney injury and signals future nephron loss.
6 citations
,
April 2016 in “Australasian journal of dermatology” Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
25 citations
,
October 2018 in “Journal of Mind and Medical Sciences” New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.
March 2023 in “The Journal of Urology” Nocturia cases increased, but medication use declined, suggesting under-treatment.
Minoxidil and nebivolol can help prevent aortic aging in diabetic mice.
1 citations
,
November 2011 in “InTech eBooks” Citrate is a safer alternative to heparin for preventing blood clots in hemodialysis.
17 citations
,
April 2007 in “Kidney international” Vitamin D boosts a specific gene activity in kidney cells that could improve heart and kidney function.
29 citations
,
June 2015 in “Kidney International” Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
September 2003 in “Reactions Weekly”
3 citations
,
May 2018 in “Biochemical and Biophysical Research Communications” iNOS contributes to hair loss in obese diabetic mice and blocking it may encourage hair growth.
21 citations
,
October 1978 in “The Journal of Clinical Pharmacology” April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
8 citations
,
October 2024 in “Cochrane Database of Systematic Reviews” Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
January 2004 in “Chinese Journal of Blood Purification” Minoxidil effectively manages severe hypertension in hemodialysis patients with minimal side effects.
39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
8 citations
,
June 2016 in “Journal of Pharmacy Practice” Lisinopril, a heart medication, probably caused hair loss in a patient, which stopped after switching drugs.
18 citations
,
January 1976 in “Drugs” New treatments improved blood pressure control in patients with resistant hypertension.
May 2004 in “International Journal of Cosmetic Science” Melanogenesis inhibitors like kojic acid and niacinamide can reduce inflammation and pigment production in skin cells.
28 citations
,
August 2013 in “Hypertension” Potassium channel openers help form elastic fibers in arteries and can treat elastin deficiency and hypertension.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.